ScholarMate
English简体中文繁體中文
客服热线:400-1616-289
登录注册
期刊论文

MicroRNA-375 is a therapeutic target for castration-resistant prostate cancer through the PTPN4/STAT3 axis

Gan, Junqing; Liu, Shan; Zhang, Yu; He, Liangzi; Bai, Lu; Liao, Ran; Zhao, Juan; Guo, Madi; Jiang, Wei; Li, Jiade; Li, Qi; Mu, Guannan; Wu, Yangjiazi; Wang, Xinling; Zhang, Xingli; Zhou, Dan; Lv, Huimin; Wang, Zhengfeng; Zhang, Yanqiao; Qian, Cheng; Feng, MeiYan; Chen, Hui; Meng, Qingwei; Huang, Xiaoyi*哈尔滨医科大学; 郑州大学; 1
Experimental and Molecular Medicine2022-8DOI: 10.1038/s12276-022-00837-6
16被引14阅读
引用收藏
分享

摘要

The functional role of microRNA-375 (miR-375) in the development of prostate cancer (PCa) remains controversial. Previously, we found that plasma exosomal miR-375 is significantly elevated in castration-resistant PCa (CRPC) patients compared with castration-sensitive PCa patients. Here, we aimed to determine how miR-375 modulates CRPC progression and thereafter to evaluate the therapeutic potential of human umbilical cord mesenchymal stem cell (hucMSC)-derived exosomes loaded with miR-375 antisense oligonucleotides (e-375i). We used miRNA in situ hybridization technique to evaluate miR-375 expression in PCa tissues, gain- and loss-of-function experiments to determine miR-375 function, and bioinformatic methods, dual-luciferase reporter assay, qPCR, IHC and western blotting to determine and validate the target as well as the effects of miR-375 at the molecular level. Then, e-375i complexes were assessed for their antagonizing effects against miR-375. We found that the expression of miR-375 was elevated in PCa tissues and cancer exosomes, correlating with the Gleason score. Forced expression of miR-375 enhanced the expression of EMT markers and AR but suppressed apoptosis markers, leading to enhanced proliferation, migration, invasion, and enzalutamide resistance and decreased apoptosis of PCa cells. These effects could be reversed by miR-375 silencing. Mechanistically, miR-375 directly interfered with the expression of phosphatase nonreceptor type 4 (PTPN4), which in turn stabilized phosphorylated STAT3. Application of e-375i could inhibit miR-375, upregulate PTPN4 and downregulate p-STAT3, eventually repressing the growth of PCa. Collectively, we identified a novel miR-375 target, PTPN4, that functions upstream of STAT3, and targeting miR-375 may be an alternative therapeutic for PCa, especially for CRPC with high AR levels. @@@ Prostate cancer: stem cell treatment targets microRNA A microRNA shown to promote prostate cancer growth can be targeted through a treatment derived from stem cells. Prostate cancer is lethal for many men, and its growth is promoted by testosterone. However, some "castration-resistant" strains keep growing even after treatments that reduce testosterone levels. Xiaoyi Huang at Harbin Medical University Cancer Hospital, China, and co-workers examined the role of microRNA-375 in the progression of castration-resistant prostate cancer. They found that microRNA-375 was over-expressed in cancer tissue samples and promoted tumor growth by interfering with a specific signaling pathway. The team applied a treatment comprising extracellular vesicles called exosomes that are derived from human stem cells and loaded with molecules that suppress microRNA-375. The treatment inhibited microRNA-375 and thereby repressed the cancer growth, while also reducing the cancer's resistance to the testosterone-blocking drug enzalutamide.

学科与关键词

关键词
SQUAMOUS-CELL CARCINOMAANDROGEN-RECEPTORINHIBITIONEXPRESSIONPROLIFERATIONMIR-375PATHWAY
相关
加载中…
  • Cancer-derived exosomal miR-375 targets DIP2C and promotes osteoblastic metastasis and prostate cancer progression by regulating the Wnt signaling pathway
    Liu, Ying; Yang, Changmou; Chen, Shisheng; Liu, Weihao; Liang, Jingyi; He, Shuhua*; Hui, Jialiang*Cancer Gene Therapy, 2023, 30(3): 437-449.被引 5
  • Exosomal miR-1275 Secreted by Prostate Cancer Cells Modulates Osteoblast Proliferation and Activity by Targeting the SIRT2/RUNX2 Cascade
    Zou, Zihao*; Dai, Ranran; Deng, Nan; Su, Wei; Liu, PingCell Transplantation, 2021, 30: 09636897211052977.被引 6
  • State-of-the-art therapeutic strategies for targeting cancer stem cells in prostate cancer
    Ramesh, Saravanan; Selvakumar, Preethi; Ameer, Mohamed Yazeer; Lian, Sen; Abdullah Alzarooni, Abdulqadir Ismail M.; Ojha, Shreesh; Mishra, Anshuman; Tiwari, Ashutosh; Kaushik, Ajeet; Jung, Young Do; Chouaib, Salem; Lakshmanan, Vinoth-Kumar*Frontiers in Oncology, 2023, 13: 1059441.被引 2
查看全部 →

发表信息

论文状态
公开发表
期刊
Experimental and Molecular Medicine
发表日期
2022-08
卷期
第 54 卷, 第 8 期
页码
1290-1305
DOI
10.1038/s12276-022-00837-6
语言
ENGLISH
期刊等级
2区
成果收录
SCIE
资助标注
National Natural Science Foundation of China [81572528, 82173184]; Outstanding Youth Fund of Heilongjiang Province [JC2018024]; CSCO-Hengrui Tumor Research Fund [Y-HR2020ZD-0361]; Haiyan Fund of Harbin Medical University Cancer Hospital [JJZD2022-02, JJQN2019-06, JJQN2019-19]

作者

  • G

    Gan, Junqing (第一作者)

    harbin med univ

  • L

    Liu, Shan

    harbin med univ

查看全部 24 位作者收起作者
  • Z

    Zhang, Yu

    harbin med univ

  • H

    He, Liangzi

    harbin med univ

  • B

    Bai, Lu

    harbin med univ

  • L

    Liao, Ran

    harbin med univ

  • Z

    Zhao, Juan

    harbin med univ

  • G

    Guo, Madi

  • J

    Jiang, Wei

    harbin med univ

  • L

    Li, Jiade

    harbin med univ

  • L

    Li, Qi

    harbin med univ

  • M

    Mu, Guannan

    harbin med univ

  • W

    Wu, Yangjiazi

    harbin med univ

  • W

    Wang, Xinling

    harbin med univ

  • Z

    Zhang, Xingli

    harbin med univ

  • Z

    Zhou, Dan

    harbin med univ

  • L

    Lv, Huimin

    harbin med univ

  • W

    Wang, Zhengfeng

    1 · zhengzhou univ

  • Z

    Zhang, Yanqiao

    harbin med univ

  • Q

    Qian, Cheng

    harbin med univ

  • F

    Feng, MeiYan

    harbin med univ

  • C

    Chen, Hui

    harbin med univ

  • M

    Meng, Qingwei

    harbin med univ

  • H

    Huang, Xiaoyi (通讯)

    harbin med univ

登录解锁更多功能

  • 收藏这篇,随时在“我的 · 收藏”找回
  • 认领你的成果,生成推广素材
  • 关注作者获取最新成果
  • 加入项目组、协同写作
注册 / 登录

产品服务

  • 科研之友
  • 创新城
  • 科创云

服务支持

  • 帮助中心
  • 隐私政策
  • 服务条款

联系方式

在线客服:【】
客服热线:400-1616-289
电子邮箱:support@scholarmate.com

关注或下载科研之友

微信二维码
微信公众号
客户端下载二维码
下载客户端
科研成果科研人员科研机构科研动态爱瑞思软件

©2026 深圳市科研之友网络服务有限公司

公安备案图标粤公网安备 44030502000213
粤ICP备 16046710 号粤B2-20110417